Cargando…

1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities

BACKGROUND: Men with prostate cancer are often challenged to choose between conservative management and a range of available treatment options each carrying varying risks and benefits. The trade-offs are between an improved life-expectancy with treatment accompanied by important risks such as urinar...

Descripción completa

Detalles Bibliográficos
Autores principales: Meghani, Salimah H, Lee, Christopher S, Hanlon, Alexandra L, Bruner, Deborah W
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789058/
https://www.ncbi.nlm.nih.gov/pubmed/19941668
http://dx.doi.org/10.1186/1472-6947-9-47
_version_ 1782175023532867584
author Meghani, Salimah H
Lee, Christopher S
Hanlon, Alexandra L
Bruner, Deborah W
author_facet Meghani, Salimah H
Lee, Christopher S
Hanlon, Alexandra L
Bruner, Deborah W
author_sort Meghani, Salimah H
collection PubMed
description BACKGROUND: Men with prostate cancer are often challenged to choose between conservative management and a range of available treatment options each carrying varying risks and benefits. The trade-offs are between an improved life-expectancy with treatment accompanied by important risks such as urinary incontinence and erectile dysfunction. Previous studies of preference elicitation for prostate cancer treatment have found considerable heterogeneity in individuals' preferences for health states given similar treatments and clinical risks. METHODS: Using latent class mixture model (LCA), we first sought to understand if there are unique patterns of heterogeneity or subgroups of individuals based on their prostate cancer treatment utilities (calculated time trade-off utilities for various health states) and if such unique subgroups exist, what demographic and urological variables may predict membership in these subgroups. RESULTS: The sample (N = 244) included men with prostate cancer (n = 188) and men at-risk for disease (n = 56). The sample was predominantly white (77%), with mean age of 60 years (SD ± 9.5). Most (85.9%) were married or living with a significant other. Using LCA, a three class solution yielded the best model evidenced by the smallest Bayesian Information Criterion (BIC), substantial reduction in BIC from a 2-class solution, and Lo-Mendell-Rubin significance of < .001. The three identified clusters were named high-traders (n = 31), low-traders (n = 116), and no-traders (n = 97). High-traders were more likely to trade survival time associated with treatment to avoid potential risks of treatment. Low-traders were less likely to trade survival time and accepted risks of treatment. The no-traders were likely to make no trade-offs in any direction favouring the status quo. There was significant difference among the clusters in the importance of sexual activity (Pearson's χ(2 )= 16.55, P = 0.002; Goodman and Kruskal tau = 0.039, P < 0.001). In multinomial logistic regression, the level of importance assigned to sexual activity remained an independent predictor of class membership. Age and prostate cancer/at-risk status were not significant factors in the multinomial model. CONCLUSION: Most existing utility work is undertaken focusing on how people choose on average. Distinct clusters of prostate cancer treatment utilities in our sample point to the need for further understanding of subgroups and need for tailored assessment and interventions.
format Text
id pubmed-2789058
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-27890582009-12-05 1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities Meghani, Salimah H Lee, Christopher S Hanlon, Alexandra L Bruner, Deborah W BMC Med Inform Decis Mak Research Article BACKGROUND: Men with prostate cancer are often challenged to choose between conservative management and a range of available treatment options each carrying varying risks and benefits. The trade-offs are between an improved life-expectancy with treatment accompanied by important risks such as urinary incontinence and erectile dysfunction. Previous studies of preference elicitation for prostate cancer treatment have found considerable heterogeneity in individuals' preferences for health states given similar treatments and clinical risks. METHODS: Using latent class mixture model (LCA), we first sought to understand if there are unique patterns of heterogeneity or subgroups of individuals based on their prostate cancer treatment utilities (calculated time trade-off utilities for various health states) and if such unique subgroups exist, what demographic and urological variables may predict membership in these subgroups. RESULTS: The sample (N = 244) included men with prostate cancer (n = 188) and men at-risk for disease (n = 56). The sample was predominantly white (77%), with mean age of 60 years (SD ± 9.5). Most (85.9%) were married or living with a significant other. Using LCA, a three class solution yielded the best model evidenced by the smallest Bayesian Information Criterion (BIC), substantial reduction in BIC from a 2-class solution, and Lo-Mendell-Rubin significance of < .001. The three identified clusters were named high-traders (n = 31), low-traders (n = 116), and no-traders (n = 97). High-traders were more likely to trade survival time associated with treatment to avoid potential risks of treatment. Low-traders were less likely to trade survival time and accepted risks of treatment. The no-traders were likely to make no trade-offs in any direction favouring the status quo. There was significant difference among the clusters in the importance of sexual activity (Pearson's χ(2 )= 16.55, P = 0.002; Goodman and Kruskal tau = 0.039, P < 0.001). In multinomial logistic regression, the level of importance assigned to sexual activity remained an independent predictor of class membership. Age and prostate cancer/at-risk status were not significant factors in the multinomial model. CONCLUSION: Most existing utility work is undertaken focusing on how people choose on average. Distinct clusters of prostate cancer treatment utilities in our sample point to the need for further understanding of subgroups and need for tailored assessment and interventions. BioMed Central 2009-11-27 /pmc/articles/PMC2789058/ /pubmed/19941668 http://dx.doi.org/10.1186/1472-6947-9-47 Text en Copyright ©2009 Meghani et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Meghani, Salimah H
Lee, Christopher S
Hanlon, Alexandra L
Bruner, Deborah W
1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
title 1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
title_full 1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
title_fullStr 1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
title_full_unstemmed 1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
title_short 1842676957299765Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
title_sort 1842676957299765latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789058/
https://www.ncbi.nlm.nih.gov/pubmed/19941668
http://dx.doi.org/10.1186/1472-6947-9-47
work_keys_str_mv AT meghanisalimahh 1842676957299765latentclassclusteranalysistounderstandheterogeneityinprostatecancertreatmentutilities
AT leechristophers 1842676957299765latentclassclusteranalysistounderstandheterogeneityinprostatecancertreatmentutilities
AT hanlonalexandral 1842676957299765latentclassclusteranalysistounderstandheterogeneityinprostatecancertreatmentutilities
AT brunerdeborahw 1842676957299765latentclassclusteranalysistounderstandheterogeneityinprostatecancertreatmentutilities